• There are no suggestions because the search field is empty.

MHRA to Launch RegulatoryConnect Portal in the UK: A New Era in Regulatory Management 

Calander_icon
person-image
Peter Fry, Country Manager UK at QbD Group

The Medicines and Healthcare Products Regulatory Agency (MHRA) recently announced the upcoming launch of the RegulatoryConnect portal, a groundbreaking step forward in regulatory management. 

MHRA to Launch RegulatoryConnect Portal in the UK: A New Era in Regulatory Management  | QbD Group
3:46

During a webinar held on March 12, 2024, they unveiled the features of Release 1 of this innovative portal, previously known as the “RMS” or “Regulatory Management System”.  

Set to go live in the week of March 25, 2024, RegulatoryConnect is designed to evolve into the ultimate gateway for all interactions with the agency, as outlined in their 2023-26 corporate plan and 2023-24 business plan.

 

RegulatoryConnect:
Simplifying Processes, Enhancing Transparency

RegulatoryConnect aims to simplify the regulatory process, offering key functionalities that promise to improve the efficiency and transparency of the MHRA’s services.

The portal will initially include features such as “Track my case“, allowing users to see the progress of their applications, thereby aiming to significantly reduce the weekly enquiries currently received by the agency. 

Users will also benefit from email notifications that provide updates on their submissions and the ability to view live authorisation details under “See my data“, ensuring greater transparency and convenience.

These services, refreshed every 24 hours, mark just the beginning of what RegulatoryConnect plans to offer. Only applications currently under validation by the agency will be visible, but this is a step towards comprehensive access and interaction with the MHRA.

 

Parallel Developments and Future Enhancements

In addition to the launch of the RegulatoryConnect portal, the MHRA is also implementing parallel activities to further enhance the information available to agency staff and stakeholders.

This includes the introduction of a new eCTD software solution, revalidation of existing sequences in the agency’s archive, and improved data reporting capabilities through PowerBI for the GxP inspectorate.

The MHRA is also in the process of importing historical data from legacy systems, ensuring ongoing management and application of standardized terms and IDMP methodologies.

It’s important to note that application submissions will continue via MHRA Submissions until the release of RegulatoryConnect Release 2, expected before the end of 2024

This next phase will introduce a UK-specific application form and replace the current portals for Product Licensing (PL) and Process Licensing (PCL) submissions.

 

Looking Ahead: Release 3 in 2025

The journey with RegulatoryConnect does not stop at Releases 1 & 2. The MHRA is already planning for Release 3 in 2025, which currently aims to implement features around submissions for the Early Access to Medicines Scheme (EAMS), Borderline products, the Import Notification Scheme for Unlicensed Medicines, Devices Registration, Approved Bodies and requests for Certificates of Free Sale. 

The agency is also considering the timelines for the integration of additional services to enhance the portal’s scope. This includes exploring the inclusion of submissions for ILAP, IDAP, PIP, PSUR, eCigarettes, Windsor Framework, and Customer Service Centre enquiries in future releases.

While the use of RegulatoryConnect for submissions related to Clinical Trial Authorisations, Clinical Investigations, and Scientific Advice are under consideration as separate projects, these features are not planned for the initial releases.

The launch of Release 1 of RegulatoryConnect marks a significant milestone in the MHRA’s commitment to providing a single point of access for all interactions with the agency.

The MHRA is dedicated to continuously improving its services and supporting the needs of its stakeholders through this innovative portal. 

 

Seeking expert regulatory guidance? 

Do you require support with navigating regulations in the UK or EU? Our team of experts will collaborate closely with you to understand your business needs and objectives and then offer specialised solutions to assist you in accomplishing them. With our expert guidance, you can confidently navigate pharmaceutical regulations. 

 

 

 
 
 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Case study

A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader​

QbD Group streamlines linguistic reviews for a leading pharma client, ensuring compliance and accuracy across 25 EU/EEA languages while meeting stringent regulatory deadlines.
preview_image
Whitepaper

Medical Device Regulation (MDR) Checklist

Implement the Medical Device Regulation (MDR) with ease. Download our checklist of mandatory documents for MDR compliance.
preview_image
Whitepaper

Regulatory Affairs for Pharma and Biotech

In this flyer, you will learn more about the regulatory services QbD Group provides for the pharmaceutical and biotechnology industries.
preview_image
Whitepaper

Clinical Evaluation for Medical Devices under MDR

This whitepaper will guide you through crucial regulatory documents pertaining to the clinical evaluation process of your medical device. Download now!
preview_image
Whitepaper

IVDR extension: what does this mean for you?

In this whitepaper, you will learn the impact of the IVDR transition extension and receive tips and strategies to navigate these regulatory changes.
preview_image
Webinar

Drug-Device Combination Products and Article 117

Explore the regulatory complexities of Drug-Device Combination Products. Learn about Article 117 requirements, Notified Body Opinions, and more.
preview_image
Whitepaper

Mobile health on the rise: exploring the regulatory landscape for reimbursement

This whitepaper will help you navigate the maze of the DTx regulatory environment, highlighting several important countries and regulations.
preview_image
Whitepaper

Clinical investigations under MDR: key insights and practical experiences

This whitepaper covers clinical investigation authorization under MDR, the EU Legal Representative's role, and the MDR's impact on study conduct and post-market surveillance.
preview_image
Case study

CE Mark Renewal for bioXtra Products: A Success Story

Discover how Lifestream Pharma successfully renewed the CE mark for their BioXtra Dry Mouth products under the EU MDR. Learn about the challenges faced, the approach taken for compliance, and the results achieved.
preview_image
Webinar

Technical Documentation Essentials for Medical Device Software

Gain practical insights on crafting MDR-compliant technical documentation for Medical Device Software.
preview_image
Webinar

Getting Started: Overcoming Initial Obstacles in Medical Device Software Development

Watch our webinar on demand and learn about regulatory obstacles, MDR, AI Act, and best practices for medical device software development and market entry.
preview_image
Webinar

Mastering Clinical Performance Studies under IVDR

In the evolving regulatory landscape of IVDs, demonstrating clinical performance is more crucial and challenging than ever. Discover more in this webinar on demand.
preview_image
Whitepaper

Clinical evidence for In Vitro Diagnostics under IVDR

In this whitepaper, we will guide you through the documents required for the demonstration of clinical evidence under the IVDR. Download now.
preview_image
Webinar

Post-Market Surveillance Requirements for Medical Devices and IVDs

Learn about post-market surveillance requirements under MDR and IVDR regulations. Gain insights from industry experts in this on-demand webinar.
preview_image
Whitepaper

The key role of Regulatory Affairs in the pharmaceutical industry: from drug development to commercialization

Discover the key role of Regulatory Affairs in pharma and how Regulatory Affairs teams support product lifecycle management in this whitepaper. Download now.
preview_image
Webinar

3D Printing in the Healthcare World

Explore the challenges and opportunities of 3D printing in healthcare, featuring expert insights on regulations, pitfalls, and efficiency.
preview_image
Webinar

IVDR Extension Explained: Tips & Strategies

Gain valuable insights on the IVDR extension and its impact on IVD manufacturers with our webinar on demand.
preview_image
Whitepaper

Innovations in ATMP: state of the industry in 2024

This whitepaper explores the innovations in ATMP and solutions in detail, with a focus on the current landscape as of April 2024. Download now.
preview_image
Case study

The journey toward IVDR compliance for the LVOne device

QbD Group helped Upfront Diagnostics gain entry into the MD/IVD industry by supporting them on their path to ISO 13485 certification.
preview_image
Case study

Ensuring a smooth MDR transition for Oystershell's medical devices

The landscape of medical device regulations is constantly evolving, making it a challenge for companies to keep up. Our collaboration with Oystershell, which began in July 2023, highlights our expertise in transforming complex challenges into success stories, all with a touch of QbD Clinical magic.
preview_image
Case study

Successful clinical evaluation supports rapid CE marking of Minze Health's Uroflowmeter

QbD Clinical assisted Minze Health, a urology-focused medical devices company, in obtaining CE marking under MDR through clinical evaluation.
preview_image
Webinar

The Medical Device CE Certification Pathway Explained: From Classification to Conformity Assessment by the Notified Body

Learn about the Medical Device CE Certification Pathway, from classification to conformity assessment by a Notified Body. Join our webinar on demand.
preview_image
Case study

Helping Relu to comply with changing regulations

QbD Group supported software company Relu with their expertise to comply with changing regulations.
preview_image
Case study

Quickly bringing a new COVID-19 medical device to market

Obtaining the required government certifications for a medical device is always a challenge. Especially when the COVID clock is ticking.